ONO-7913-02 : ONO-7913 Phase 1 Study
Phase 1
- Conditions
- Myelodysplastic Syndrome (MDS)
- Registration Number
- JPRN-jRCT2031210139
- Lead Sponsor
- Osawa Masahiro
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
1. Patients with histological confirmation of MDS defined according to WHO classification, with an IPSS-R risk category of intermediate, high, or very high risk
2. Patients judged by the investigator or subinvestigator to be appropriate for treatment with azacitidine
3. Patients with ECOG Performance Status of 0 to 1
Exclusion Criteria
1. Patients who are determined to undergo allogeneic hematopoietic stem cell transplantation
2. Patients previously treated with azacitidine
3. Patients with severe complication
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method